As per DelveInsight’s assessment, the Companion Diagnostics Devices Market is expected to grow at an immense pace in the coming years owing to the The increasing prevalence of pandemic such as COVID-19, Pre- and post-operation and some few of the other applications where Companion Diagnostics Devices have been used, which is expected to drive the demand for Companion Diagnostics Devices in the upcoming years.
DelveInsight’s “Companion Diagnostics Devices Market” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Companion Diagnostics Devices companies actively working in the market.
Companion Diagnostics Devices Overview
A companion diagnostic is a medical device that offers data necessary for the safe and efficient use of a corresponding medication or biological product. These devices are frequently in vitro devices.
Companion Diagnostics Devices Market Insights
The global cancer case rate is increasing exponentially, which is one of the main causes driving the demand for companion diagnostics. The need for companion diagnostics has also been strengthened by the patient population’s growing awareness of precision medicine and the manufacturers’ increasing attention to this field of study. Moreover, growing approvals and product launches of companion diagnostics, along with increased research and development for companion diagnostics for non-cancer disorders, are some of the major factors expected to boost the global market for companion diagnostics during the forecast period (2023–2028).
DelveInsight Analysis: The Global Companion Diagnostics Devices market size is anticipated to reach ~USD 11.89 billion by 2028 with a growing CAGR of 12.32% during the forecasted period (2023-2028).
To know more about why North America is leading the market growth in the Companion Diagnostics Devices market, get a snapshot of the report Companion Diagnostics Devices Market Trends
https://www.delveinsight.com/report-store/companion-diagnostics-market
Recent Developments in the Companion Diagnostics Devices Market Report
- In March 2022, Myriad Genetics received FDA approval of BRACAnalysis® CDx as a companion diagnostic for Lynparza® in early breast cancer.
- In October 2021, Agilent was granted the FDA approval for its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) as a companion diagnostics in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.
- In August 2021, Roche received FDA approval for the first companion diagnostic to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy.
To read more about the latest highlights related to Companion Diagnostics Devices, get a snapshot of the key highlights entailed in the Companion Diagnostics Devices Market Forecast Report
Key Players in the Companion Diagnostics Devices Market
Some of the key market players operating in the Companion Diagnostics Devices market include- Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories., QIAGEN, BIOMÉRIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories., Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of America® Holdings., SAGA Diagnostics, and others.
COVID-19 Impact Analysis on the Companion Diagnostics Devices Market
North America is anticipated to be the region with the largest share of the global companion diagnostics market in 2022 and to maintain this position throughout the forecast period. This is because different cancers are becoming more common and causing more cases in the area. Complementary diagnostics market factors include advantageous reimbursement regulations, the approval and introduction of different companion diagnostic devices in the region, the business expansion initiatives taken by local enterprises, and others.
Additionally, It is also anticipated that major manufacturers will shift their focus to the development of companion diagnostics for a variety of non-cancer disorders, including Huntington’s disease, Alzheimer’s disease, and others. This will help in the management and treatment of these diseases and enhance patient outcomes. So, during the projected period, the market for Companion Diagnostics Devices is anticipated to continue expanding (2023-2028).
Scope of the Companion Diagnostics Devices Market Report
- Coverage: Global
- Study Period: 2020–2028
- Companion Diagnostics Devices Market Segmentation By Therapy Type: Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], and others
- Companion Diagnostics Devices Market Segmentation By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others
- Companion Diagnostics Devices Market Segmentation By End User: Hospitals, Specialty Clinics, And Others
- Companion Diagnostics Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
- Key Companion Diagnostics Devices Companies: Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott Laboratories., QIAGEN, BIOMÉRIEUX, Guardant Health Inc., Illumina, Inc., Pillar Biosciences, Inc., Leica Biosystems, Thermo Fisher Scientific Inc., Almac Group, NeoGenomics Laboratories., Invitae Corporation, 3D Medicines Corporation, ASURAGEN, INC. (Biotechne), Invivoscribe, Inc., Amoy Diagnostics Co., Ltd., Laboratory Corporation of America® Holdings., SAGA Diagnostics, and others
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the Companion Diagnostics Devices market are set to emerge as the trendsetter explore @ Companion Diagnostics Devices Manufacturer
Table of Contents
|
1 |
Companion Diagnostics Devices Market Report Introduction |
|
2 |
Companion Diagnostics Devices Market Executive summary |
|
3 |
Regulatory and Patent Analysis |
|
4 |
Companion Diagnostics Devices Market Key Factors Analysis |
|
5 |
Porter’s Five Forces Analysis |
|
6 |
COVID-19 Impact Analysis on Companion Diagnostics Devices Market |
|
7 |
Companion Diagnostics Devices Market Layout |
|
8 |
Global Company Share Analysis – Key 3-5 Companies |
|
9 |
Company and Product Profiles |
|
10 |
Companion Diagnostics Devices Market Drivers |
|
11. |
Companion Diagnostics Devices Market Barriers |
|
12. |
Project Approach |
|
13. |
About DelveInsight |
Interested in knowing how the Companion Diagnostics Devices market will grow by 2028? Click to get a snapshot of the Companion Diagnostics Devices Market Analysis
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services